Your browser doesn't support javascript.
loading
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine.
Conway, Sarah; Saxena, Shrishti; Baecher-Allan, Clare; Krishnan, Rajesh; Houtchens, Maria; Glanz, Bonnie; Saraceno, Taylor J; Polgar-Turcsanyi, Mariann; Bose, Gauruv; Bakshi, Rohit; Bhattacharyya, Shamik; Galetta, Kristin; Kaplan, Tamara; Severson, Christopher; Singhal, Tarun; Stazzone, Lynn; Zurawski, Jonathan; Paul, Anu; Weiner, Howard L; Healy, Brian C; Chitnis, Tanuja.
Afiliação
  • Conway S; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Saxena S; Harvard Medical School, Boston, MA, USA.
  • Baecher-Allan C; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Krishnan R; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Houtchens M; Harvard Medical School, Boston, MA, USA.
  • Glanz B; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Saraceno TJ; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Polgar-Turcsanyi M; Harvard Medical School, Boston, MA, USA.
  • Bose G; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Bakshi R; Harvard Medical School, Boston, MA, USA.
  • Bhattacharyya S; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Galetta K; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Kaplan T; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Severson C; Harvard Medical School, Boston, MA, USA.
  • Singhal T; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Stazzone L; Harvard Medical School, Boston, MA, USA.
  • Zurawski J; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Paul A; Harvard Medical School, Boston, MA, USA.
  • Weiner HL; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
  • Healy BC; Harvard Medical School, Boston, MA, USA.
  • Chitnis T; Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Mult Scler J Exp Transl Clin ; 9(2): 20552173231165196, 2023.
Article em En | MEDLINE | ID: mdl-37057191
ABSTRACT

Background:

There is limited knowledge about T cell responses in patients with multiple sclerosis (MS) after 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine.

Objectives:

Assess the SARS-CoV-2 spike antibody and T cell responses in MS patients and healthy controls (HCs) after 2 doses (2-vax) and 3 doses (3-vax) of SARS-CoV-2 mRNA vaccination.

Methods:

We studied seroconversion rates and T cell responses by flow cytometry in HC and MS patients on fingolimod or ocrelizumab.

Results:

After 2-vax, 8/33 (24.2%) patients in ocrelizumab group, 5/7 (71.4%) in fingolimod group, and 29/29 (100%) in HC group (P = 5.7 × 10-11) seroconverted. After 3-vax, 9/22 (40.9%) patients in ocrelizumab group, 19/21 (90.5%) in fingolimod group, and 7/7 (100%) in HC group seroconverted (P = 0.0003). The percentage of SARS-CoV-2 peptide reactive total CD4+ T cells increased in HC and ocrelizumab group but not in fingolimod group after 2-vax and 3-vax (P < 0.0001). The percentage of IFNγ and TNFα producing total CD4+ and CD8+ T cells increased in fingolimod group as compared to HC and ocrelizumab group after 2-vax and 3-vax (P < 0.0001).

Conclusions:

MS patients on ocrelizumab and fingolimod had attenuated humoral responses, but preserved cytokine producing T cell responses compared to HCs after SARS-CoV-2 mRNA vaccination. Clinical Trials Registration NCT05060354.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article